2,280 press releases in English indexed under biotech & pharma.
WATERTOWN, Mass., October 02, 2026--Dyno Therapeutics presents new multi-mechanism muscle capsid data at the 31st international Congress of the World Muscle Society
Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase...
DELRAY BEACH, Fla., Oct. 2, 2026 -- According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9% during the forecast period. Browse 420 market data Tables and 50 Figures...
ZUG, Switzerland and BOSTON, Oct. 02, 2026 -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.
LARKSPUR, Calif., October 02, 2026--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
REDWOOD CITY, Calif., October 02, 2026--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation targeted therapies for cancer, today announced an upcoming poster presentation of preclinical data on PHST001 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place from November 4-8 in Phoenix, AZ. PHST001 is a first-in-class anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment and is
LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and...
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes
Historic first-ever honor makes the M34 co-founder the only scientist to receive Founders Awards from leading gene and cell therapy societies across three continents CHAPEL HILL, N.C., Oct. 2, 2026 -- M34 Inc. today announced that its co-founder and chief scientific officer,...
DALLAS, Oct. 02, 2026 -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees restricted stock units (RSUs) representing 384,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment. The RSUs and stock option were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
PARSIPPANY, N.J., Oct. 02, 2026 -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data include a post hoc analysis of safety and efficacy during the initial 8 weeks of treatment with ecopipam, long-term efficacy and safety from an interim analysis of an ongoing open-label extension (OLE) study, post hoc subgroup analyses and preclinical receptor selectivity findings.